Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial
Maria Fleseriu, Alexander Dreval, Irina Bondar, et al.
The Lancet Diabetes & Endocrinology (2021) Vol. 10, Iss. 2, pp. 102-111
Open Access | Times Cited: 39

Showing 1-25 of 39 citing articles:

Acromegaly: pathogenesis, diagnosis, and management
Maria Fleseriu, Fabienne Langlois, Dawn Shao Ting Lim, et al.
The Lancet Diabetes & Endocrinology (2022) Vol. 10, Iss. 11, pp. 804-826
Closed Access | Times Cited: 133
Consensus on criteria for acromegaly diagnosis and remission
Andrea Giustina, Nienke R. Biermasz, Felipe F. Casanueva, et al.
Pituitary (2023)
Open Access | Times Cited: 79
Personalized Medical Treatment of Patients With Acromegaly: A Review
Dawn Shao Ting Lim, Maria Fleseriu
Endocrine Practice (2022) Vol. 28, Iss. 3, pp. 321-332
Closed Access | Times Cited: 24
Diagnosis and therapeutic approach to bone health in patients with hypopituitarism
Justyna Kuliczkowska-Płaksej, Aleksandra Zdrojowy-Wełna, Aleksandra Jawiarczyk-Przybyłowska, et al.
Reviews in Endocrine and Metabolic Disorders (2024) Vol. 25, Iss. 3, pp. 513-539
Closed Access | Times Cited: 5
Octreotide subcutaneous depot for acromegaly: A randomized, double-blind, placebo-controlled phase 3 trial, ACROINNOVA 1
Diego Ferone, Pamela U. Freda, Laurence Katznelson, et al.
The Journal of Clinical Endocrinology & Metabolism (2024)
Open Access | Times Cited: 5
MPOWERED Trial Open-Label Extension: Long-term Efficacy and Safety Data for Oral Octreotide Capsules in Acromegaly
Maria Fleseriu, Mark E. Molitch, Alexander Dreval, et al.
The Journal of Clinical Endocrinology & Metabolism (2023) Vol. 108, Iss. 12, pp. 3214-3222
Open Access | Times Cited: 12
Structure and Function of Somatostatin and Its Receptors in Endocrinology
Bo Zhang, Xue Li, Zhe Wu
Endocrine Reviews (2024) Vol. 46, Iss. 1, pp. 26-42
Open Access | Times Cited: 4
“Cold” Somatostatin Analogs in Neuroendocrine Neoplasms: Decoding Mechanisms, Overcoming Resistance, and Shaping the Future of Therapy
Sara Massironi, Manuela Albertelli, Iderina Hasballa, et al.
Cells (2025) Vol. 14, Iss. 4, pp. 245-245
Open Access
Promising therapies for the treatment of acromegaly
Sylvère Störmann, Katharina Schilbach
Expert Opinion on Pharmacotherapy (2025)
Closed Access
Pasireotide effects on biochemical control and glycometabolic profile in acromegaly patients switched from combination therapies or unconventional dosages of somatostatin analogs
Giuliana Corica, Rosa Pirchio, Angelo Milioto, et al.
Journal of Endocrinological Investigation (2023) Vol. 47, Iss. 3, pp. 683-697
Closed Access | Times Cited: 10
Treatment of acromegaly with oral octreotide
Ilan Remba-Shapiro, Lisa B. Nachtigall
Best Practice & Research Clinical Endocrinology & Metabolism (2024) Vol. 38, Iss. 4, pp. 101888-101888
Closed Access | Times Cited: 3
Durable biochemical response and safety with oral octreotide capsules in acromegaly
Susan L. Samson, Lisa B. Nachtigall, Maria Fleseriu, et al.
European Journal of Endocrinology (2022) Vol. 187, Iss. 6, pp. 733-741
Open Access | Times Cited: 15
Octreotide attenuates intestinal barrier damage by maintaining basal autophagy in Caco2 cells
Xiaoli Liu, Yan Zhou, Yu Zhang, et al.
Molecular Medicine Reports (2024) Vol. 29, Iss. 6
Open Access | Times Cited: 2
Clinical Pharmacology of Oral Octreotide Capsules for the Treatment of Acromegaly
Meliha Melin Uygur, Marta Villanova, Stefano Frara, et al.
touchREVIEWS in Endocrinology (2024) Vol. 20, Iss. 1
Open Access | Times Cited: 2
Medical treatment of functional pituitary adenomas, trials and tribulations
Cristina Căpățînă, Felicia A. Hanzu, José Miguel Hinojosa‐Amaya, et al.
Journal of Neuro-Oncology (2024) Vol. 168, Iss. 2, pp. 197-213
Closed Access | Times Cited: 2
Oral octreotide capsules for acromegaly treatment: application of clinical trial insights to real-world use
Maria Fleseriu, Lisa B. Nachtigall, Susan L. Samson, et al.
Expert Review of Endocrinology & Metabolism (2024) Vol. 19, Iss. 4, pp. 367-375
Open Access | Times Cited: 2
Innovative therapeutics in acromegaly
Leandro Kasuki, Mônica R. Gadelha
Best Practice & Research Clinical Endocrinology & Metabolism (2022) Vol. 36, Iss. 6, pp. 101679-101679
Closed Access | Times Cited: 9
Treatment of acromegaly with the nonpeptide, highly selective somatostatin receptor type 2 agonist paltusotine
Luiz Eduardo Wildemberg, Christhiane Fialho, Mônica R. Gadelha
Best Practice & Research Clinical Endocrinology & Metabolism (2024) Vol. 38, Iss. 4, pp. 101906-101906
Closed Access | Times Cited: 1
The Efficacy and Safety of Somatostatin Analog after Axillary Node Dissection in Breast Cancer: A Systematic Review and Meta-analysis
Satsuki Hirono, Jun Watanabe, Atsushi Miki, et al.
JMA Journal (2023) Vol. 6, Iss. 3, pp. 274-281
Open Access | Times Cited: 3
Oral Octreotide: A Review of Recent Clinical Trials and Practical Recommendations for Its Use in the Treatment of Patients With Acromegaly
Kevin C.J. Yuen, Susan L. Samson
Endocrine Practice (2022) Vol. 28, Iss. 6, pp. 637-645
Closed Access | Times Cited: 5
Circumventing the Gastrointestinal Barrier for Oral Delivery of Therapeutic Proteins and Peptides (PPTS): Current Trends and Future Trajectories
Lily Ellysa Hashim, Akmal Hidayat Sabri, Malihah Athirah Mohamad, et al.
Current Drug Delivery (2023) Vol. 21, Iss. 2, pp. 211-235
Closed Access | Times Cited: 2
Celebrating a Century of Insulin Discovery: A Critical Appraisal of the Emerging Alternative Insulin Delivery Systems
Ntethelelo Sibiya, Bonisiwe Mbatha, Phikelelani Ngubane, et al.
Current Drug Delivery (2022) Vol. 20, Iss. 6, pp. 656-668
Closed Access | Times Cited: 4
Clinical Management of Acromegaly: Therapeutic Frontiers and New Perspectives for Somatostatin Receptor Ligands (SRLs)
Alessandro Brunetti, Simone Antonini, Andrea Saladino, et al.
Medicina (2022) Vol. 58, Iss. 6, pp. 794-794
Open Access | Times Cited: 4
Advances in the Oral Administration of Somatostatin Receptor Ligands in Acromegaly: A Systematic Review Focusing on Biochemical Response
Clémence Reverdiau, Damien Denimal
Pharmaceutics (2024) Vol. 16, Iss. 11, pp. 1357-1357
Open Access
Are Oral Somatostatin Receptor Ligands Moving Closer to Becoming a Reality?
David S. McLaren, Nikolaos Kyriakakis, Khyatisha Seejore, et al.
Clinical Endocrinology (2024) Vol. 102, Iss. 3, pp. 288-290
Closed Access
Page 1 - Next Page

Scroll to top